Phesgo is a cancer medicine for treating adults with ‘HER2-positive’ breast cancer (where a protein called HER2 is found on the cancer cells). It is used in combination with other cancer medicines in: - patients with early breast cancer (when the cancer has not spread to other parts of the body) at high risk of coming back, after they have surgery; - patients with locally advanced, inflammatory breast cancer or with early breast cancer at high risk of coming back, before they have surgery; - patients whose cancer that has come back locally after treatment and cannot be removed by surgery; - patients with metastatic breast cancer (cancer that has spread to other parts of the body). Phesgo contains the active substances pertuzumab and trastuzumab. For more information about the use of Phesgo and the other medicines the patients will receive, see the package leaflet.
Therapeutic Indication
### Therapeutic indication **Early breast cancer (EBC)** Phesgo is indicated for use in combination with chemotherapy in: - the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence - the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence **Metastatic breast cancer (MBC)** Phesgo is indicated for use in combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.
Therapeutic Area (MeSH)
N/AATC Code
L01XY
ATC Item
抗肿瘤的复方
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
N/AINN / Common Names
N/AEMA Name
Phesgo
Medicine Name
Phesgo
Aliases
N/ANo risk management plan link.
